Novo Nordisk A/S Common Stock (NVO)

Novo Nordisk stock has multiple catalysts that could soon reverse is slide.

These companies own 97% of the weight loss drug market -- which could grow tenfold over the next decade -- and are developing next-generation offerings.

The company is planning to soon begin combination studies, testing two of its drugs in weight loss.

Chugai plans to pair its muscle-preserving drug with Eli Lilly's orforglipron, addressing muscle loss in obesity care as the market expands rapidly.

With its stock plummeting over the past year, Novo Nordisk is waving goodbye to its top executive. What might the future hold for the weight-loss drug kingpin?

Amgen is hoping to take on Eli Lilly and Novo Nordisk with a potential monthly shot, MariTide.

Semaglutide drugs now include rare vision risk warning as studies link long-term use to optic neuropathy, macular degeneration, and kidney cancer.

Shares of Novo Nordisk Inc. (NYSE: NVO) are trading lower Tuesday after a new study raised concerns about a potential link between GLP-1 weight loss drugs like Ozempic and an increased risk of kidney cancer.

Regeneron highlighted that about 35% of weight loss from semaglutide alone was due to lean mass loss, which combo therapies aim to reduce.

NOVO-NORDISK (NYSE:NVO) offers strong growth, solid profitability, and reasonable valuation, making it a compelling choice for investors seeking affordable growth stocks.

Eli Lilly is rapidly encroaching on Novo Nordisk's yearslong lead in GLP-1 drugs. Can Novo hold its tentpole position?

NOVO-NORDISK (NYSE:NVO) offers strong profitability, solid growth, and reasonable valuation, making it a compelling choice for value investors. Its financial health and industry-leading margins add further appeal.

Ozempic helped Novo Nordisk gain an early lead in the weight loss industry, but competition is nipping at the company's heels.